KIT and gastrointestinal stromal tumor: Around 85% of sporadic primary GIST harbor activating mutations in either the KIT (65%) or PDGFRA gene (20%) [17], both encoding type III RTKs, and are variably sensitive to RTK-inhibitors, mainly Imatinib.